Cilag AG International

6 articles about Cilag AG International

• Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab

  6/7/2021

  Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets CD70.

• Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

  12/3/2018

  Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain

• Johnson & Johnson's Subsidiary, Cilag AG International, to Shed 120 Jobs in Schaffhausen

  1/12/2012

• Cilag AG International Completes $245 Million Acquisition of Over-the-Counter Brands of JB Chemicals & Pharmaceuticals Limited

  7/14/2011

• The Day In Review: MGI PHARMA, INC. Sells Ex-US Dacogen Rights

  7/6/2006

• SuperGen, Inc. Announces Attainment Of Milestone From The MGI PHARMA, INC. / Cilag GmbH, A Johnson & Johnson, Licensing For Dacogen(TM) (Decitabine) For Injection

  7/6/2006